• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BU professor fabricates data in two published experiments

BU professor fabricates data in two published experiments

August 10, 2011
CenterWatch Staff

A cancer researcher and assistant professor at the Boston University School of Medicine Cancer Research Center fabricated data in two papers published in scientific journals, federal authorities announced, according to a report by the Boston Globe.

Sheng Wang, an assistant professor whose research involved molecular biology approaches to understanding cancer, no longer works at BU.  Wang has agreed to retract the two papers and will not be eligible for or involved in federally funded research for two years, according to the finding of research misconduct issued by the Office of Research Integrity of the HHS.

The federal authorities found that Wang engaged in research misconduct in projects supported by two federal grants from the National Cancer Institute. According to the federal finding, Wang fabricated experiments used in six out of seven figures in one paper and six out of eight figures in the other. He is listed as the senior author on both papers, which were published in 2009 and explored the role of a gene that suppresses tumor growth.

The sanctions described in the misconduct findings include Wang’s agreement to exclude himself from receiving funds or working for any US government agency for two years. He is also barred from serving on advisory or peer review committees, or as a consultant for the government’s Public Health Service.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing